Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition)

Abstract

Metastatic hormone-sensitive prostate cancer (mHSPC) is a male health concern requiring continuous attention. In 2021, an important update was included in domestic and international guidelines regarding the recommendations of initial systemic therapy for mHSPC, in which androgen deprivation therapy (ADT) combined with novel hormone therapy (NHT) has became the most important systemic treatment strategy. Meanwhile, emerging technologies and concepts, such as local therapy for the primary tumor in mHSPC, metastasis-directed therapy (MDT), genetic testing, and next generation imaging (NGI), have developed rapidly to promote further changes in the pattern of diagnosis and treatment of mHSPC. There are significant differences observed between China and western countries including genetics, screening policy, disease stage distribution and clinical characteristics at diagnosis. Focus on the controversial issues related to the clinical management of mHSPC in China, Chinese Prostate Cancer Consortium (CPCC) organized multidisciplinary experts to screen key decision-making questions based on the latest evidence. After multiple rounds of voting and discussion, the “Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition)” is finally formed, aiming to provide a decision-making reference for clinical management of mHSPC in the real-world.

Keywords

• |metastatic hormone-sensitive prostate cancer|novel hormone therapy|clinical management|precise diagnosis|multi-model therapy